Project description
Novel customisable platform for predicting clinical trial outcomes
Treatment plans, drugs and devices destined for human use must first be tested in clinical studies, a time-consuming and costly process. Clinical trial success does not only rely on science but is largely dependent on the initial design, development and management process. To improve clinical trial outcomes, the EU-funded iMOTED project has developed software that combines real-time data from multiple sources to simulate and predict clinical trial results. The iMOTED platform is simple to implement and is expected to assist the industry in launching new therapeutics by minimising associated economic losses.
Objective
                                Clinical Trials (CT) are designed to prove if a drug, device or therapy is safe and effective in the human body, so they are already tested in individuals. The CT investigators and sponsors spend great amount of resources on data management and project and data quality control. In 2017 more than 120,000 CT have been registered, of which near 31,000 are carried out in the EU. Usually the average duration of CT from start to marketing is 7.5 years, however, more than 80% of CT are delayed from 1 to 6 month costing to the companies upwards of 30,000 € per day per trial. In most of the cases, this delay is due to inefficient management systems. With CT conducted in over 140 countries, the complexity and rate of change in trials is increasing. Considering this huge business opportunity, we have been working in a customizable software system to manage and simplify CT development. iMOTED platform will ensure high quality data, collected from multiple sources by using real time analysis of data, a simple and intuitive interface, generation of real time alarms employing estimations, predictions & simulations 
In this way, we expect to reduce the economic losses that pharma industry has when launching a new drug, for whom only 2 out of 10 marketed drugs return revenues that exceed R&D costs. 
iMOTED belongs to the e-clinic market, which is forecasted to reach €7.6 Bn by 2022 growing at a CARG of 12.4% over the period 2017-2022. We will initially target Europe as our domestic market, to start selling the IMOTED licenses. We expect to have our breakeven point two years after the beginning of the project, a cumulative turnover of €13 M by 2022, that will give us a ROI of 560% in 2024. Hence, at this stage of development we believe that we need to perform a through feasibility study to assess for the challenges and tasks that we still must accomplish to launch iMOTED for what we are asking for EC support.
                            
                                Fields of science (EuroSciVoc)
                                                                                                            
                                            
                                            
                                                CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See:   The European Science Vocabulary.
                                                
                                            
                                        
                                                                                                
                            CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences computer and information sciences data science big data
- natural sciences computer and information sciences software software applications system software
- medical and health sciences health sciences personalized medicine
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
            Programme(s)
            
              
              
                Multi-annual funding programmes that define the EU’s priorities for research and innovation.
                
              
            
          
                      Multi-annual funding programmes that define the EU’s priorities for research and innovation.
- 
                  H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs
                                      MAIN PROGRAMME
                                    
 See all projects funded under this programme
- 
                  H2020-EU.3. - PRIORITY 'Societal challenges
                                    
 See all projects funded under this programme
- 
                  H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies
                                    
 See all projects funded under this programme
            Topic(s)
            
              
              
                Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
                
              
            
          
                      
                  Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
            Funding Scheme
            
              
              
                Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
                
              
            
          
                      Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
                Call for proposal
                
                  
                  
                    Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
                    
                  
                
              
                              Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-EIC-SMEInst-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
20009 SAN SEBASTIAN DONOSTIA
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.
 
           
        